VV 116 tablet meets primary endpoint in phase III trial versus Paxlovid for early treatment of mild to moderate COVID-19.
This announcement is made by Shanghai Junshi Biosciences Co., Ltd. pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as well as the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Please also refer to the overseas regulatory announcement of the Company published on 23 May 2022.
The board of directors of the Company is pleased to announce that the product VV 116 tablet (project code: JT001/VV116, an oral nucleoside analog anti-SARS-CoV-2 drug jointly developed by Shanghai JunTop Biosciences Co., Ltd. , a subsidiary controlled by the Company, and Vigonvita Life Sciences Co., Ltd., reached its primary endpoint in a phase III registrational clinical study (NCT05341609) of VV 116 versus nirmatrelvir tablet/ritonavir tablet (namely Paxlovid for early treatment of mild to moderate coronavirus disease 2019 (“COVID-19”). The Company will communicate with the regulatory authority in respect of the submission of new drug application (“NDA”) in the near future.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins